Drug intelligence / Profile preview

amikacin + cefoxitin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Inhalation

Overview

A combination antibiotic therapy consisting of amikacin (an aminoglycoside) and cefoxitin (a cephamycin antibiotic). This combination is primarily used for treating infections caused by resistant bacteria, particularly Mycobacterium abscessus. Amikacin works by binding to bacterial ribosomes and inhibiting protein synthesis, while cefoxitin inhibits bacterial cell wall synthesis. The combination is often used with a third drug, clarithromycin, as a standard treatment regimen for M. abscessus infections, though studies have shown limited efficacy against macrolide-resistant strains.

Targets

Bacterial RibosomePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on amikacin + cefoxitin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amikacin + cefoxitin.

Explore the full profile